Clinical Trials Directory

Trials / Completed

CompletedNCT00958880

Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety

Placebo-Controlled Evaluation of the Efficacy of Yohimbine Hydrochloride for Enhancing the Effects of CBT for Social Phobia

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Southern Methodist University · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to investigate the utility of Yohimbine hydrochloride for facilitating fear extinction in a sample of patients with social phobia who will be treated with CBT.

Detailed description

The primary aim is to determine the relative efficacy of exposure-based CBT for social phobia when conducted with adjunctive acute (prior to four of five sessions) administration of either Yohimbine hydrochloride (10.8 mg) or placebo during core exposure sessions. Based on the available evidence, the investigators hypothesize that acute treatment with Yohimbine hydrochloride prior to exposure-based CBT would facilitate the extinction of fear that occurs with this treatment and would enhance treatment outcome.

Conditions

Interventions

TypeNameDescription
BEHAVIORALGroup Cognitive Behavioral Therapy5 weeks of group CBT for Social Anxiety. The aim of CBT is to help participants become more comfortable with social situations One arm will receive placebo augmented Group Cognitive Behavioral Therapy and the other will receive yohimbine hydrochloride augmented cognitive behavioral therapy.
DRUGYohimbine HydrochlorideParticipants in the Yohimbine augmented arm will receive 4 doses of Yohimbine Hydrochloride before 4 of the 5 group cognitive behavioral therapy sessions.
DRUGSugar PillParticipants in the placebo (sugar pill) augmented arm will receive 4 doses of a sugar pill before 4 of the 5 group cognitive behavioral therapy sessions.

Timeline

Start date
2009-03-01
Primary completion
2013-01-01
Completion
2013-01-01
First posted
2009-08-13
Last updated
2013-11-11
Results posted
2013-11-11

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00958880. Inclusion in this directory is not an endorsement.